Mas Receptor Agonism Attenuates Seizures in a Pentylenetetrazole Kindling Model of Experimental Epilepsy in Mice
Long-term administration of the Mas receptor agonist AVE 0991 attenuates PTZ-induced seizure severity, anxiety, and cognitive impairment in mice by modulating MasR, NR2B, and BDNF mRNA expression, suggesting its potential as a therapeutic strategy for epilepsy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Epilepsy is a condition where the brain's electrical signals become chaotic, leading to sudden, uncontrolled seizures. For many people, standard medications work well, but about one-third of patients find their seizures resistant to these drugs, leaving them searching for new ways to control the condition. Scientists have long known that the brain contains complex chemical systems that regulate how neurons communicate and protect themselves from damage. One such system, known as the renin-angiotensin system, is famous for controlling blood pressure, but it also exists within the brain, where it helps manage inflammation and cell survival. Within this system, there is a specific pathway involving a receptor called MasR that acts as a protective switch, potentially calming overactive brain cells and reducing the damage caused by stress or injury. Understanding how to turn this switch on could offer a new way to treat epilepsy and the anxiety or memory problems that often accompany it.
A team of researchers at universities in Turkey set out to test whether activating this protective MasR switch could stop seizures in mice. They used a well-established method to create a chronic epilepsy model, repeatedly injecting a chemical called pentylenetetrazole into the animals. This chemical blocks a calming signal in the brain, eventually training the brain to have severe seizures similar to those seen in humans. The researchers then divided these epileptic mice into groups. Some received a harmless salt solution, while others received a drug called AVE 0991, which is designed to specifically turn on the MasR receptor. They tested the drug in two ways: giving it just once before a seizure attempt, and giving it daily for two weeks to see if long-term treatment changed the brain's behavior.
The results showed that a single dose of the drug did nothing to stop the seizures. However, the story changed completely with the long-term treatment. Mice that received the drug daily for fourteen days experienced significantly milder seizures. When they did have a seizure, it started later, lasted for a shorter time, and involved fewer chaotic electrical spikes than in the untreated mice. The most effective dose was 10 milligrams per kilogram of body weight. This long-term treatment also improved the animals' behavior. Epilepsy often causes anxiety and memory loss in both humans and animals, and the untreated mice in this study showed clear signs of fear and confusion. The mice treated with the drug, however, acted more like healthy animals; they were less anxious, explored their environment more boldly, and remembered their way through mazes much better.
To understand why the drug worked, the researchers looked inside the brains of the mice after the experiments. They found that the long-term treatment increased the number of MasR receptors in the cortex and hippocampus, the brain regions responsible for thinking and memory. This suggests that the drug not only activated the existing receptors but also encouraged the brain to build more of them, strengthening its natural defense system. Furthermore, the drug corrected a molecular imbalance caused by the seizures. In the untreated mice, the brain showed a dangerous overactivity of certain genetic instructions, specifically mRNA for NR2B and BDNF, which are linked to excessive electrical firing and cell stress. The drug successfully reduced these levels back toward normal, helping to restore balance to the brain's signaling.
The study concludes that while a single dose of this MasR activator is ineffective, a sustained course of treatment can significantly reduce seizure severity, delay the onset of seizures, and improve the quality of life for the animals by reducing anxiety and memory loss. The researchers suggest that this approach, which works by boosting the brain's own protective mechanisms and calming its overactive signals, holds promise as a new therapeutic target for epilepsy. They note that while the findings are encouraging, more research is needed to fully understand how this pathway works and to determine if it can be safely translated to human medicine. For now, the work provides a clear demonstration that keeping the MasR switch turned on over time can help the brain resist the chaos of epilepsy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.